ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Group trials need prioritization, review, NCI official says.

July 25, 2003

Also Unclear whether HHS Secretary Tommy Thompson will depart as previously planned.

November 5, 2004

New Carfilzomib Combination Produces Near Remissions

June 29, 2012

Stand Up To Cancer Co-Founder Laura Ziskin Dies of Complications From Breast Cancer at 61

June 17, 2011

ACR Defends Mammographic Exams For Women 35-40,Says Carcinogenic Threat Is “Small”

July 30, 1976

In Brief: NCI Grants Get More Money, Pay Line Boosted To 193

May 22, 1981